ten23 health

As a CDMO, ten23 health does not have its own clinical results. It provides formulation development, analytical testing, process development, fill & finish manufacturing for sterile injectable medicines to pharma and biotech clients at all stages from pre-clinical to commercial supply. The company emphasizes sustainability and human-centric approaches and was certified as a B Corp in August 2024. They support clients in developing differentiated, stable, usable, and safe injectable treatments for patients. They are the first CDMO in the pharmaceutical industry for injectables/sterile drug products to have been certified as a B Corp. Their operations include ten23’s Basel development lab and swissfillon’s scaled fill & finish manufacturing. No proprietary pipeline or clinical-stage assets.